FDA-cleared profile

CT Rembra RT; CT Areta RT; CT Rembra

Philips Healthcare (Suzhou) Co., Ltd. · CT/CTA · FDA-cleared (510(k))

Authorized purpose: CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.

Clinical role
CT acquisition, reconstruction, visualization, and release-specific examination planning.
Images and patients
CT/CTA · Multi-region
Key limitation
Keep in mind: The screening must be performed within the established inclusion criteria of programs/protocols that have been approved and published by either a governmental body or a professional medical society.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.
  • Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Multi-region Input: X-ray transmission data taken at different angles and planes.
  • Who uses it?Intended users: Only trained and qualified users, certified in accordance with country-specific regulations, are authorized to operate the system.
  • What does the software produce?Output: The acquired x-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. It produces CT images in DICOM format.
  • What is its most important limitation?Key limitation: The screening must be performed within the established inclusion criteria of programs/protocols that have been approved and published by either a governmental body or a professional medical society.

Clinical takeaway. Clinical role: CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.

Evidence takeaway. Evidence from the reviewed source record: K252992 reports system, reconstruction, image-quality, radiation-safety, software, and workflow validation for the listed radiology and large-bore oncology configurations.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
CT Rembra RT, CT Areta RT, and CT Rembra support whole-body diagnostic imaging, oncology, radiotherapy planning, interventional, vascular, neurological, cardiovascular, and qualified lung-screening workflows for all ages.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
CT acquisition, reconstruction, visualization, and release-specific examination planning.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
X-ray transmission data taken at different angles and planes.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications and device description state this acquisition input wording.

Output and clinician action
The acquired x-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. It produces CT images in DICOM format.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description states reconstructed cross-sectional DICOM CT images, not the current generalized measurements/planning-dataset list.

Care setting
Hospital and outpatient CT, interventional, oncology, or radiotherapy departments within the cleared scope.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Only trained and qualified users, certified in accordance with country-specific regulations, are authorized to operate the system.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description states this authorization boundary rather than the current technologist/physician role list.

Limitations
The screening must be performed within the established inclusion criteria of programs/protocols that have been approved and published by either a governmental body or a professional medical society.
  • Exact FDA submission
  • Checked 2026-09-19

This is the exact packet's explicit low-dose CT lung-screening boundary; the current local-acceptance language is not stated in the packet.

Evidence summary
K252992 reports system, reconstruction, image-quality, radiation-safety, software, and workflow validation for the listed radiology and large-bore oncology configurations.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K252992 reports system, reconstruction, image-quality, radiation-safety, software, and workflow validation for the listed radiology and large-bore oncology configurations.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this acquisition, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K252992 FDA performance package for CT Rembra RT; CT Areta RT; CT Rembra

  • DesignManufacturer nonclinical CT system, reconstruction, image-quality, safety, and workflow validation
  • PopulationBroad pediatric and adult diagnostic, oncology, and radiotherapy-planning CT applications
  • Scopeexact submission
  • Tested versionCT Rembra RT, CT Areta RT, and CT Rembra release cleared in K252992
  • IndependenceSponsor or vendor study

K252992

Manufacturer evidence submitted for clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K252992 by exact submission identifier. This does not exclude product-family or later safety information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: X-ray transmission data taken at different angles and planes.

    Scope: Exact FDA submission. The exact indications and device description state this acquisition input wording.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K252992: CT Rembra RT; CT Areta RT; CT Rembra

  2. Routing

    Source context, not route validation: Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K252992: CT Rembra RT; CT Areta RT; CT Rembra · Philips Rembra RT CT simulator · Philips CT technical reference guide

  3. AI processing

    Source context, not route validation: Installed CT scanner hardware, console software, reconstruction options, and supported accessories.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K252992: CT Rembra RT; CT Areta RT; CT Rembra · Philips Rembra RT CT simulator · Philips CT technical reference guide

  4. Returned objects

    Source context, not route validation: The acquired x-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. It produces CT images in DICOM format.

    Scope: Exact FDA submission. The exact device description states reconstructed cross-sectional DICOM CT images, not the current generalized measurements/planning-dataset list.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K252992: CT Rembra RT; CT Areta RT; CT Rembra

  5. Viewer/worklist/report

    Unresolved route: The acquired x-ray transmission data is reconstructed by computer into cross-sectional images of the body taken at different angles and planes. It produces CT images in DICOM format.

    Scope: Exact FDA submission. The exact device description states reconstructed cross-sectional DICOM CT images, not the current generalized measurements/planning-dataset list.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K252992: CT Rembra RT; CT Areta RT; CT Rembra

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed CT scanner hardware, console software, reconstruction options, and supported accessories.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.
  • Exact FDA submission
  • Checked 2026-09-03
Security
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.

Training
Only qualified ct technologists and trained interpreting or treating physicians. should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream compatibility acceptance remains required.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K252992 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Scanner-console and DICOM workflow to PACS, advanced visualization, and treatment-planning systems; validate worklist, protocol, dose record, geometry, series labels, and routing.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream compatibility acceptance remains required.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Use only cleared populations, protocols, reconstructions, and applications; local dose, image-quality, geometry, and downstream compatibility acceptance remains required.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252992
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The exact packet classifies the devices as a Computed Tomography X-Ray System and does not state the current CTA modality label. Controlled directory display reconciled from exact FDA wording: Computed Tomography X-Ray System. -> CT/CTA.

Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-03-23
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
0Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate record. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 0 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision material, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

9 sources - 3 history items

Source ledger

  1. FDA K252992: CT Rembra RT; CT Areta RT; CT Rembra

    U.S. Food and Drug Administration - Published 2026-03-23 - Accessed 2026-09-19

    Scope: purpose, anatomy, evidenceSummary, modality, intendedUsers, input, output, limitations, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Philips Rembra RT CT simulator

    Philips - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  8. Philips CT technical reference guide

    Philips - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  9. Philips: Responsible Disclosure Statement

    Philips - Accessed 2026-10-26

    Scope: security

Research history

  1. K252992 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253649

Spectral CT Verida Family

Philips Medical Systems Technologies, Ltd.

Authorized purpose: Spectral CT Verida Family supports the labeled spectral CT acquisition, reconstruction, material-map, and professional-interpretation workflow; exact models, protocols, and derived outputs remain submission-specific.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-27
FDA-cleared K253574

SOMATOM X.cite; SOMATOM X.ceed

Siemens Medical Solutions USA, Inc.

Authorized purpose: SOMATOM X.cite and X.ceed with syngo CT VB20 support diagnostic CT, interventions, treatment preparation, radiation-therapy planning, and qualified low-dose lung screening.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-20
FDA-cleared K253944

Data Analysis Facilitation Suite (DAFS)

Voronoi Health Analytics Incorporated

Authorized purpose: DAFS automatically segments anatomy on DICOM Part 10 CT images and supports reviewed two- and three-dimensional visualization, editing, and area, volume, and intensity measurements; it does not provide diagnostic interpretation.

Modality
CT/CTA
Anatomy
Multi-region
Decision
2026-03-16

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history